Post-Test Evaluating Current and Emerging Targeted Therapies in Hepatocellular Carcinoma (2023) Post-Test Which of the following TKIs is approved as first-line therapy for patients with HCC? Cabozantinib Lenvatinib Ramucirumab Regorafenib According to the National Comprehensive Cancer Network (NCCN) guidelines, which of the following TKIs is recommended as subsequent therapy following disease progression for HCC patients with a baseline AFP level of 400 ng/mL or greater? Cabozantinib Ramucirumab Regorafenib Sorafenib Which of the following TKI and ICI combination regimens demonstrated the longest median OS reported for first-line therapy in phase 3 HCC studies? Cabozantinib plus atezolizumab Cabozantinib plus nivolumab Lenvatinib plus pembrolizumab Lenvatinib plus toripalimab For patients with HCC treated with cabozantinib, which of the following is recommended for the management of grade 3 or higher hand-foot skin reactions? Dose reduction or interruption Permanent discontinuation Topical exfoliation Use of emollients How often do you/will you consider the use of TKI and ICI combination regimens for the management of patients with HCC? Always Often Sometimes Rarely Never Previous
